MALVERN, Pa., April 20 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc., , a specialty pharmaceutical company, today announced that Ms. Gerri Henwood, Chief Executive Officer, and Mr. Jim Fickenscher, Chief Financial Officer, will participate in the annual UBS Specialty Pharmaceuticals Conference to be held April 24-25, 2006 at the Grand Hyatt Hotel in New York, NY. Ms. Henwood is scheduled to present an overview of the Company and its product pipeline at 10:30 AM Eastern time on Tuesday, April 25, 2006.
To listen to the audio webcast of the presentation during or after the event, please visit: http://www.auxilium.com . The replay will be available for 30 days after the event.
About Auxilium Pharmaceuticals
Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on developing and marketing products for urology, sexual health and other indications within specialty markets. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 120-person sales and marketing team. Auxilium has five projects in clinical development. Auxilium believes that AA4500, an injectable enzyme, has completed Phase II of development for the treatment of Dupuytren’s Disease and is in Phase II of development for the treatment of Peyronie’s Disease and Frozen Shoulder Syndrome (Adhesive Capsulitis). Auxilium believes that its testosterone replacement transmucosal film product candidate for the treatment of hypogonadism (AA2600) has completed Phase II of development and is about to enter Phase III of development. Auxilium’s transmucosal film product candidate for the treatment of overactive bladder (AA4010) is in Phase I of development. Auxilium has two pain products using its transmucosal film delivery system in pre-clinical development. Auxilium has rights to six additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system, options to all indications using AA4500 for non-topical formulations, and other products for urology and sexual health. For additional information, visit http://www.auxilium.com .
Safe Harbor Statement
This release contains “forward-looking-statements” within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to present at the UBS conference, the timing for the commencement of various clinical trials for Auxilium’s product candidates during 2006, if at all; and products in development for pain, urology and sexual health. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company’s Annual Report on Form 10-K for the period ended December 31, 2005 under the heading “Risk Factors”, which is on file with the Securities and Exchange Commission (the “SEC”) and may be accessed electronically by means of the SEC’s home page on the Internet at http://www.sec.gov or by means of the Company’s home page on the Internet at http://www.auxilium.com under the heading “Investor Relations - SEC Filings.” There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements.
In addition, forward-looking statements provide the Company’s expectations, plans or forecasts of future events and views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward- looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this release.
Auxilium Pharmaceuticals, Inc.
CONTACT: James E. Fickenscher/CFO, Auxilium Pharmaceuticals, Inc.,+1-484-321-5902, jfickenscher@auxilium.com; Gregory Gin of Lazar Partners,Ltd., +1-212-867-1762, ggin@lazarpartners.com, for Auxilium
Web site: http://www.auxilium.com/
